THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018. 

Craven House Capital plc

("Craven House" or the "Company")

Investee company update: Bio Vitos

Further to the announcement of 3 July 2023 at 01:32pm Craven House announces that the transaction between its investee company, Bio Vitos, and Hemcheck Sweden AB ("Hemcheck") has received approval from Nasdaq Stockholm. Bio Vitos will now proceed to completion of the transaction which is anticipated during September, 2023. Upon completion  Bio Vitos will  own 259,654,000 shares in Hemcheck.. This amounts to  88.3% of Hemcheck's share capital.

 Craven House's holding in Bio Vitos will remain unchanged.

The full text of the announcement released by Hemcheck today has been translated and set out below:

" PRESS RELEASE

Hemcheck has been conditionally approved for continued listing by Nasdaq and can complete the transaction with Bio Vitos

Hemcheck has been approved for continued listing by Nasdaq, subject to the transaction with Bio Vitos being carried out and other customary conditions such as updating the website after the transaction is completed.

With this, the company description that has been produced is published and this can also be found on the company's website, www.hemcheck.se. This also means that the transaction with Bio Vitos, where IP rights and capital are acquired, can be completed.

The company will quickly implement all the steps required to complete the transaction with Bio Vitos. Additional information will be shared as soon as final dates are determined.

For further information please contact:

About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.